# A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

> **NCT05365100** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **BioNova Pharmaceuticals (Shanghai) LTD.**

## Conditions studied

- CLL/SLL
- NHL

## Interventions

- **DRUG:** BN102

## Key facts

- **NCT ID:** NCT05365100
- **Lead sponsor:** BioNova Pharmaceuticals (Shanghai) LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to company decision
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05365100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05365100, "A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05365100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*